MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
July 25, 2012
MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter - Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
June 8, 2011 / Pharmacogenomics Reporter - AutoGenomics Gets FDA Clearance for CYP2C19 Test, But Cannot Mention Plavix PGx
October 27, 2010 / Pharmacogenomics Reporter - FDA Updates Plavix Label with PGx Data, but Does Not Provide Dosing Recommendations
June 17, 2009 / Pharmacogenomics Reporter